2026-01-29 - Analysis Report
**Company Overview:**

RTX Corporation is the global leader in advanced propulsion and aerospace systems.

**Return Rate Comparison with S&P 500 (VOO):**

* Cumulative Return of Review Stock: 172.47%
* Cumulative Return of Comparison Stock (S&P 500, VOO): 128.51%
* Divergence: 44.96% (current: 46.50, max: 48.70, min: -57.90, relative divergence: 97.90%)
* The divergence between the review stock and the S&P 500 is significant, with the review stock having a higher cumulative return.

**Alpha, Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | -3.0% | 23.4% | -11.0% | 0.9 | 89.8B |
| 2017-2019 | 23.0% | 23.4% | -2.0% | 1.0 | 126.4B |
| 2018-2020 | -25.0% | 51.0% | -49.0% | 1.2 | 95.9B |
| 2019-2021 | 19.0% | 51.0% | -46.0% | 1.2 | 115.4B |
| 2020-2022 | 11.0% | 51.0% | 6.0% | 1.0 | 135.3B |
| 2021-2023 | 21.0% | 28.9% | 3.0% | 0.7 | 112.8B |
| 2022-2024 | 31.0% | 28.9% | 2.0% | 0.6 | 155.2B |
| 2023-2025 | 107.0% | 28.9% | 32.0% | 0.5 | 245.9B |

The review stock has a range of CAGR from -3.0% to 107.0% across different years, with a maximum MDD of 51.0%. The Beta value ranges from 0.6 to 1.2, indicating a moderate correlation with the market.

**Recent Stock Price Fluctuations:**

* Close: $199.39
* Last-Market Change: -0.94 ( previous close: $201.28)
* 5-day SMA: $197.41
* 20-day SMA: $193.21
* 60-day SMA: $181.93

The review stock has a slight decline in the last market day, but the 5-day and 20-day SMA indicate a slight upward trend.

**Analysis of RSI, PPO Index Indicators, and Delta_Previous_Relative_Divergence:**

* Market Risk Indicator (MRI): 0.70 (0.9~1.0: High Investment Recommended, 0.7~0.9: Medium Investment, 0.4~0.7: Low Investment, <0.4: Very Risky)
* RSI: 69.35
* PPO: -0.08
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: 0.70 (+): improving
* 7-day Rank change: 54 (+): rank up
* 7-day Dynamic Expected Return change: 95.90 (+): improving
* Expected Return (%): -6.40%, Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

The review stock has a medium-risk rating, with a moderate RSI value and a slightly positive PPO value. The hybrid signal indicates a buy signal with a cash value of 0%.

**Recent News & Significant Events:**

* [2026-01-27] RTX, Northrop Grumman Rise In Defense-Heavy Earnings Week - Investor's Business Daily (news.google.com)
* [2026-01-27] Why RTX Stock Popped Today - Yahoo Finance (news.google.com)
* [2026-01-27] RTX shares rise after Q4 earnings and revenue beat (RTX:NYSE) - Seeking Alpha (news.google.com)
* [2026-01-27] RTX Stock Jumps as Defense Giant Beats Earnings Forecasts - TipRanks (news.google.com)
* [2026-01-27] Consumer confidence sinks, UPS layoffs, RTX ignores Trump threats - Yahoo Finance (news.google.com)
* [2026-01-26] RTX (RTX) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance (news.google.com)

The recent news suggests that the review stock has beaten earnings and revenue expectations, leading to a sharp increase in its price.

**Analyst Opinions:**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.14 (~Buy)
- Opinions: 21
- Target Price (avg/high/low): 209.73 / 235.00 / 150.00

The analysts have a consensus of "buy" on the review stock, with a mean opinion of 2.14 and a target price range of $150.00 to $235.00.

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
|-----|----|---------|
| 2025-10-21 | 1.43 | $22.48B |
| 2025-07-22 | 1.24 | $21.58B |
| 2025-04-22 | 1.15 | $20.31B |
| 2024-10-22 | 1.1 | $20.09B |
| 2025-10-21 | 1.1 | $20.09B |

The review stock has consistently beaten earnings expectations, with an average EPS of $1.23 and a revenue of $21.41B.

**Financial Information:**

Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $22.48B | 20.38% |
| 2025-06-30 | $21.58B | 20.28% |
| 2025-03-31 | $20.31B | 20.27% |
| 2024-12-31 | $21.62B | 19.59% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $64.51B | 2.97% |
| 2025-06-30 | $62.40B | 2.66% |
| 2025-03-31 | $61.52B | 2.50% |
| 2024-12-31 | $60.16B | 2.46% |

The review stock has a steady revenue and profit margin across different quarters, with an average revenue of $21.43B and a profit margin of 20.19%. The equity has been increasing steadily, with an average equity of $62.14B.

**Comprehensive Analysis (Summary of previous items):**

The review stock has a strong performance in terms of revenue, profit margin, and equity. The analysts have a consensus of "buy" on the stock, with a mean opinion of 2.14 and a target price range of $150.00 to $235.00. The short-term indicators suggest a slight upward trend, while the long-term indicators indicate a moderate risk rating. Overall, the review stock appears to be a good investment option with a potential for long-term growth.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.